Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Autoimmune Limbic Encephalitis with GAD Antibodies
The Neurohospitalist 1:178-181, Finelli, P.F., 2011
Voltage-gated Potassium Channel-associated Limbic Encepahlitis in the West of Scotland:Case Reports and Literature Review
Scott Med J 54:27-31, Reid,J.M.,et al, 2009
Non-Paraneoplastic Limbic Encephalitis Associated with Anti-Glutamic Acid Decarboxylase Antibodies
J Neuroimmunol 199:155-159, Mata,S.,et al, 2008
Plasma Exchange for Anti GAD Associated Non Paraneoplastic Limbic Encephalitis
Transfus Apher Sci 39:229-233, Mazzi,G.,et al, 2008
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Clinicopath Conf
Hodgkin's Disease, Paraneoplastic Cerebellar Degeneration, Case 21-1997, NEJM 337:115-12297., , 1997
Progressive Encephalomyelitis with Rigidity Responsive to Plasmapheresis and Immunosuppression
Ann Neurol 40:451-453, Fogan,L., 1996
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Plasmapheresis and Antineoplastic Treatment in CNS paraneoplastic Syndromes with Antineuronal Autoantibodies
Neurol 42:536-540, Graus,F.,et al, 1992
Autoantibody Synthesis in the Central Nervous System of Patients with Paraneoplastic Syndromes
Neurol 40:1085-1091, Furneaux,H.F.,et al, 1990
Plasmapheresis in the Treatment of Stiff-Man Syndrome
NEJM 320:1499, Vicari,A.M.,et al, 1989
The Eaton-Lambert (Myasthenic) Syndrome in Association with Systemic Lupus Erythematosus
Arch Neurol 43:1186-1187, Hughes,R.L.&Katirji,M.B., 1986
Plasma Exchange & Immunosuppressive Drug Treatment in the Lambert-Eaton Myasthenic Syndrome
Neurol 34:480-485, Newsom-Davis,J.,et al, 1984
Plasmapheresis & Immunosuppressive Drug Therapy in the Eaton-Lambert Syndrome
Ann Neurol 11:570-575, Da,P.C.,et al, 1982
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Reversible Gait Ataxia
Neurol 88:e145-e149, Abkur, T.M. & Bede, P., 2017
Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses
Ann Neurol 79:206-216,204, Kleiter, I.,et al, 2016
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Transverse Myelitis
NEJM 363:564-572, Frohman,E.M. &Wingerchuk,D.M., 2010
Clincopath Conference, Thrombotic Thrombocyclopenic Purpura in Patient with Lupus Nephritis
NEJM 363:2352-2361, Case 37-2010, 2010
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Pathophysiology of Thrombotic Thrombocytopenic Purpura
Int J Hematol 91:1-30, Tsai, H.M., 2010
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
A Woman With Acute Myelopathy in Pregnancy: Case Outcome
BMJ 339:1372-1376, Reu�,R.,et al, 2009
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Intravenous Immunoglobulin Therapy for Miller Fisher Syndrome
Neurol 68:1144-1146, Mori,M.,et al, 2007
Idiopathic Transverse Myelitis. Corticosteroids, Plasma Exchange, or Cyclophosphamide
Neurol 68:1614-1617, Greenberg,B.M.,et al, 2007
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Plasmapheresis Improves Outcome in Postinfectious Cerebellitis Induced by Epsteiin-Barr Virus
Neurol 62:1443, Schmahmann,J.D., 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Plasma Exchange for Severe Optic Neuritis
Neurol 63:1081-1083, Ruprecht,K.,et al, 2004
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003